|
Inclusion period
| | | | | | | |
|
< July, 1996
|
15
|
9 (60%)
| |
20 ± 10
| |
33 ± 12
| |
|
> July, 1996
|
21
|
17 (81%)
|
0.26
|
43 ± 11
|
0.13
|
57 ± 11
|
0.31
|
|
Age (years)
| | | | | | | |
|
<10
|
23
|
20 (87%)
| |
48 ± 10
| |
61 ± 10
| |
|
≥ 10
|
13
|
6 (46%)
|
0.018
|
15 ± 10
|
0.01
|
23 ± 12
|
0.006
|
|
WBC (/mm
3
)
| | | | | | | |
|
<50,000
|
21
|
17 (81%)
| |
33 ± 10
| | | |
|
≥ 50,000
|
15
|
9 (60%)
|
0.26
|
33 ± 12
|
0.54
| |
0.91
|
|
<100,000
|
26
|
22 (85%)
| |
42 ± 10
| |
58 ± 10
| |
|
≥ 100,000
|
10
|
4 (40%)
|
0.014
|
10 ± 9
|
0.003
|
20 ± 13
|
0.03
|
|
Response to steroid (+3 drug intra-thecal injection) at D8
| | | | | | | |
|
poor (≥ 1000 blasts/mm3)
|
5
|
2 (40%)
| |
20 ± 18
| |
20 ± 18
| |
|
good(<1000 blasts/mm3)
|
31
|
24 (77%)
|
0.12
|
35 ± 9
|
0.33
|
52 ± 9
|
0.19
|
|
Response to chemotherapy evaluated on D21
| | | | | | | |
|
M1(≤ 5% blasts)
|
21
|
20 (95%)
| |
43 ± 11
| |
62 ± 11
| |
|
M2+M3 (>5%–25% and >25% blasts)
|
15
|
6 (40%)
|
0.0004
|
20 ± 10
|
0.18
|
27 ± 11
|
0.06
|
|
Age, D21 response and WBC
| | | | | | | |
|
Age<10 and D21 M1 and WBC count<100,000
|
14
|
14 (100%)
| |
57 ± 13
| |
79 ± 11
| |
|
Others
|
22
|
12 (55%)
|
0.003
|
18 ± 8
|
0.002
|
27 ± 9
|
0.003
|
